Horizon Blue Cross Blue Shield of New Jersey, Three Penn Plaza East, PP-13Q, Newark, NJ 07105-2200, USA.
Am J Manag Care. 2011 Jun;17 Suppl 8:S210-2.
The purpose of this retrospective study was to evaluate health plan member utilization patterns of extended-release naltrexone (XR-NTX) and assess the cost of alcohol-related hospitalizations and medical and pharmacy costs. This is the first known study that examined post-XR-NTX therapy outcomes and costs.
Retrospective analysis of claims data.
A sample of 48 members was identified with continuous pharmacy and medical benefit enrollment between July 1, 2006, and December 31, 2008, and a medical claim for reimbursement code J2315 (naltrexone for extended-release injectable suspension) with a date of service between July 1, 2007, and December 31, 2007.
The average duration of XR-NTX therapy was 3 months. Among the 40% of patients who received 3 or more months of therapy, 58% had gaps in therapy. Post-XR-NTX therapy, alcohol-related hospitalization, medical, and pharmacy costs significantly decreased.
Findings validate that abstinence from alcohol remains an issue after discontinuing therapy. Despite most patients being on therapy for less than 6 months, there were significant reductions in costs for alcohol-related hospitalizations, as well as total medical and total pharmacy costs.
本回顾性研究旨在评估健康计划成员对纳曲酮缓释片（XR-NTX）的使用模式，并评估与酒精相关的住院治疗费用以及医疗和药房费用。这是首个研究 XR-NTX 治疗后结果和成本的已知研究。
索赔数据的回顾性分析。
在 2006 年 7 月 1 日至 2008 年 12 月 31 日期间，对连续参加药房和医疗保险的 48 名成员进行了抽样，且他们在 2007 年 7 月 1 日至 2007 年 12 月 31 日期间有过 J2315（纳曲酮缓释注射混悬液）报销代码的医疗索赔。
XR-NTX 治疗的平均持续时间为 3 个月。在接受 3 个月或以上治疗的患者中，有 58%的患者治疗存在中断。在 XR-NTX 治疗后，与酒精相关的住院治疗、医疗和药房费用显著降低。
研究结果验证了在停止治疗后，患者仍然存在戒酒问题。尽管大多数患者的治疗时间不足 6 个月，但与酒精相关的住院治疗费用以及总医疗和总药房费用都显著降低。
